The US Food and Drug Administration (FDA) has approved Pfizer’s Litfulo (ritlecitinib) for use in adolescents with severe alopecia areata, an autoimmune condition that causes hair loss. The approval marks the first treatment for the psychologically damaging condition in teens. Positive results from a phase 2b/3 study, which included over 700 patients, supported the FDA’s decision..
According to Emily Kimber, “In the study, 23% of patients treated with Litfulo 50mg had 80% or more scalp hair coverage after six months, compared to 1.6% in the placebo group, with efficacy and safety results consistent between adolescent and adult patients.”
To read more, click here.
(Source: PM Live, June 26th, 2023)